One of the most striking and evident signs of aging is the increase in wrinkles on the face. This is something that occurs naturally over time as a result of biochemical, histological and physiological changes and are then further amplified by other influences, including the natural pull of gravity or the repeated facial movements caused by muscle contractions made to form facial expressions.
Argireline peptide was the first peptide launched on the market to fight against expression wrinkles acting in vitro, in the same way as Botulinum Toxin, but offering a far safer alternative to the widely-known cosmetic procedure.
Its unique mechanism of action has made a significant difference to and caused waves within the industry.
Argireline peptide works by mimicking the N-terminal end of the SNAP-25 (Synaptosomal-associated) protein and it competes with the natural protein for a position in the Snare complex – a large complex system formed by various proteins in addition to the SNAP-25 protein, which plays an important role in the release of neurotransmitters.
If the Snare complex is slightly destabilized, the vesicle cannot release neurotransmitters efficiently and therefore the muscle contraction is attenuated, preventing the formation of lines and wrinkles.
Known throughout the industry for its rapid result-delivering capabilities, the hexapeptide is effective in just one week in the significant reduction of expression lines and wrinkles in both length and volume.
In tests, wrinkle volume diminished by 20.6% and length by 15.9%, on average, which are statistically significant results. Other parameters used to describe wrinkles, like roughness and depth, were also proved in further clinical studies to have decreased.
Developed to counteract the effects of the passage of time, Argireline peptide has featured as a star ingredient within a multitude of well-known and highly successful/ award-winning beauty products internationally.
